Literature DB >> 25996039

The advantages of pulmonary delivery of therapeutic siRNA.

Daniel P Feldmann1, Olivia M Merkel.   

Abstract

Keywords:  gene therapy; inhalation; nanoparticle; pulmonary delivery; siRNA

Mesh：

Substances：

Year:  2015        PMID： 25996039     DOI： 10.4155/tde.15.8

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


× No keyword cloud information.
  9 in total

1.  Engineering of Solid Dosage Forms of siRNA-Loaded Lipidoid-Polymer Hybrid Nanoparticles Using a Quality-by-Design Approach.

Authors:  Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal:  Methods Mol Biol       Date:  2021

2.  Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread.

Authors:  Shubhankar Ambike; Cho-Chin Cheng; Martin Feuerherd; Stoyan Velkov; Domizia Baldassi; Suliman Qadir Afridi; Diana Porras-Gonzalez; Xin Wei; Philipp Hagen; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Vincent Grass; Gerald Burgstaller; Andreas Pichlmair; Olivia M Merkel; Chunkyu Ko; Thomas Michler
Journal:  Nucleic Acids Res       Date:  2022-01-11       Impact factor: 16.971

3.  Rational design of multistage drug delivery vehicles for pulmonary RNA interference therapy.

Authors:  A Sofia Silva; Kevin E Shopsowitz; Santiago Correa; Stephen W Morton; Erik C Dreaden; Teresa Casimiro; Ana Aguiar-Ricardo; Paula T Hammond
Journal:  Int J Pharm       Date:  2020-10-26       Impact factor: 5.875

4.  The impact of microfluidic mixing of triblock micelleplexes on in vitro / in vivo gene silencing and intracellular trafficking.

Authors:  Daniel P Feldmann; Yuran Xie; Steven K Jones; Dongyue Yu; Anna Moszczynska; Olivia M Merkel
Journal:  Nanotechnology       Date:  2017-05-10       Impact factor: 3.874

Review 5.  Pulmonary Delivery of siRNA via Polymeric Vectors as Therapies of Asthma.

Authors:  Yuran Xie; Olivia M Merkel
Journal:  Arch Pharm (Weinheim)       Date:  2015-07-07       Impact factor: 3.751

6.  Can pulmonary RNA delivery improve our pandemic preparedness?

Authors:  Olivia M Merkel
Journal:  J Control Release       Date:  2022-03-28       Impact factor: 11.467

Review 7.  siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?

Authors:  Aditi Mehta; Thomas Michler; Olivia M Merkel
Journal:  Adv Healthc Mater       Date:  2021-01-27       Impact factor: 11.092

8.  Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.

Authors:  Domizia Baldassi; Shubhankar Ambike; Martin Feuerherd; Cho-Chin Cheng; David J Peeler; Daniel P Feldmann; Diana Leidy Porras-Gonzalez; Xin Wei; Lea-Adriana Keller; Nikolaus Kneidinger; Mircea Gabriel Stoleriu; Andreas Popp; Gerald Burgstaller; Suzie H Pun; Thomas Michler; Olivia M Merkel
Journal:  J Control Release       Date:  2022-03-29       Impact factor: 11.467

9.  Combined Chemisorption and Complexation Generate siRNA Nanocarriers with Biophysics Optimized for Efficient Gene Knockdown and Air-Blood Barrier Crossing.

Authors:  Alexander Taschauer; Wolfram Polzer; Stefan Pöschl; Slavica Metz; Nathalie Tepe; Simon Decker; Norbert Cyran; Julia Scholda; Julia Maier; Hermann Bloß; Martina Anton; Thilo Hofmann; Manfred Ogris; Haider Sami
Journal:  ACS Appl Mater Interfaces       Date:  2020-06-23       Impact factor: 9.229
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.